Zhang Jianping, Ren Guangxu, Li Minghua, Lu Peihua, Yi Suqin
Bone Marrow Transplantation (BMT) Unit, Hebei Yanda Ludaopei Hospital, Sanhe, China.
Institute of Food and Nutrition Development, Ministry of Agriculture, Beijing, China.
Case Rep Hematol. 2019 Mar 31;2019:4505238. doi: 10.1155/2019/4505238. eCollection 2019.
Almost 90% of patients undergoing hematopoietic stem cell transplantation (HSCT) experience diarrheal episodes, which represent a severe, often life-threatening complication for these patients. Although fecal microbiota transplantation (FMT) represents an alternative treatment option for infection-related diarrhea, the application of FMT in HSCT patients is greatly restricted for safety reasons. Furthermore, the therapeutic outcomes of FMT as a diarrhea treatment are somewhat related to the choice of the FMT donor. Here, we comprehensively profiled the dynamic changes in the intestinal microbiota after FMT from two donors with different feeding patterns and the same severely diarrheal recipient undergoing HSCT via a 45-day clinical observation. Importantly, no adverse events attributed to FMT were observed. The stool volume and frequency of the patient were reduced when we used feces from donor #1 (mixed feeding), but these changes were not observed after FMT from donor #2 (exclusive breastfeeding). Interestingly, no obvious differences in overall diversity (Shannon) or richness (Chao1) between the two donors were observed. Additionally, accounted for 29.9% and 18.1% of OTUs in the stools of donors #1 and #2, respectively. accounted for 16.3% and 2.9% of the stools of donors #1 and #2, respectively. Furthermore, through longitudinal monitoring of the patient, we identified 6 OTUs that were particularly sensitive to the different FMT complements. Together, we present a case report suggesting that the overall diversity of the intestinal microbiota may not be the only important element in the selection of an effective FMT donor.
近90%接受造血干细胞移植(HSCT)的患者会出现腹泻发作,这对这些患者来说是一种严重的、往往危及生命的并发症。尽管粪便微生物群移植(FMT)是感染相关性腹泻的一种替代治疗选择,但出于安全考虑,FMT在HSCT患者中的应用受到极大限制。此外,FMT作为腹泻治疗的疗效在一定程度上与FMT供体的选择有关。在此,我们通过45天的临床观察,全面分析了来自两名喂养方式不同但同为严重腹泻的HSCT受体的供体进行FMT后肠道微生物群的动态变化。重要的是,未观察到归因于FMT的不良事件。当我们使用供体#1(混合喂养)的粪便时,患者的粪便量和频率有所减少,但在使用供体#2(纯母乳喂养)的粪便进行FMT后未观察到这些变化。有趣的是,在两个供体之间未观察到总体多样性(香农指数)或丰富度(Chao1指数)的明显差异。此外, 分别占供体#1和#2粪便中OTU的29.9%和18.1%。 分别占供体#1和#2粪便的16.3%和2.9%。此外,通过对患者的纵向监测,我们确定了6个对不同FMT补充物特别敏感的OTU。我们共同呈现了一份病例报告,表明肠道微生物群的总体多样性可能不是选择有效FMT供体的唯一重要因素。